Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat sodium in ICU patients at high risk of ARDS
ChiCTR2200064094Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sivelestat in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoints: Utilization rate of mechanical ventilation and Incidence of severe ARDS. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2200064094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064094.